atezolizumab,nivolumab,ipilimumab
bms,roche
['improve ', 'check,mate,914', 'rcc,(-irccs),(-srcc),(-urcc)', 'checkmate 914', 'immotion010']
#esmo22:adjuvant #immunotherapy does not improve dfs in #rcc: immotion010, checkmate 914 and prosper miss their primary endpoints
read the daily reporter article to know more 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.